Exhibit 107
Calculation of Filing Fee Tables
Form S-3
(Form Type)
Cullinan Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
| Security Type |
Security Title |
Fee Calculation Rule |
Amount Registered |
Proposed Maximum Offering Price Per Unit |
Maximum Aggregate Offering Price |
Fee Rate |
Amount of Registration Fee | |||||||||
| Fees to Be Paid | Equity | Common Stock, par value $0.0001 per share | 457(c) | 14,736,860(1) | $26.84(2) | $395,537,322.40 | 0.00014760 | $58,381.31 | ||||||||
| Total Offering Amounts | $395,537,322.40 | $58,381.31 | ||||||||||||||
| Total Fees Previously Paid | — | |||||||||||||||
| Total Fee Offsets | — | |||||||||||||||
| Net Fee Due | $58,381.31 | |||||||||||||||
| (1) | The shares of common stock will be offered for resale by the selling stockholders pursuant to the prospectus contained in the registration statement to which this exhibit is attached. The registration statement registers the resale of an aggregate of 14,736,860 shares of the registrant’s common stock, which consists of (i) 14,421,070 outstanding shares of common stock and (ii) 315,790 shares of common stock issuable upon the exercise of outstanding pre-funded warrants. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), the shares of common stock offered hereby and shares of common stock issuable upon exercise of pre-funded warrants also include an indeterminate number of additional shares of common stock as may from time to time become issuable by reason of stock splits, stock dividends, recapitalizations or other similar transactions. |
| (2) | This estimate is made pursuant to Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate offering price are based upon the average of the high and low prices of the registrant’s common stock as reported on The Nasdaq Global Select Market on May 13, 2024. |